<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01992094</url>
  </required_header>
  <id_info>
    <org_study_id>V130_01</org_study_id>
    <nct_id>NCT01992094</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older</brief_title>
  <official_title>A Phase III, Stratified, Randomized, Double-Blind, Multicenter, NonInferiority Study to Evaluate the Safety and Immunogenicity of a Cell-based Quadrivalent Subunit Influenza Virus Vaccine and Cell-based Trivalent Subunit Influenza Virus Vaccines in Adults Ages ≥18 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate safety and immunogenicity of three influenza vaccines in adults 18 years of age and
      above.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1.Geometric Mean Titres (GMT) in Subjects After Receiving One Dose of Either QIVc, TIV1c or TIV2c</measure>
    <time_frame>Three weeks post vaccination (Day 22)</time_frame>
    <description>Immunogenicity of QIVc to comparator TIVc (For H1N1, H3N2 and B1 strain, the comparison is between QIVc and TIV1c and for B2 i.e. alternate B strain, the comparison is between QIVc and TIV2c) was assessed in terms of GMT in subjects measured by hemagglutination inhibition (HI) assay, three weeks after vaccination with one dose of either QIVc or TIV1c and TIV2c.
Non-inferiority was established if the upper bound of the two-sided 95% confidence interval (CI) for the ratio of GMTs (GMT TIV1c or TIV2c /GMT QIVc) for HI antibody does not exceed the non-inferiority margin of 1.5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2. Percentages of Subjects Achieving Seroconversion After One Dose of Either QIVc, TIV1c or TIV2c</measure>
    <time_frame>Three weeks post vaccination (Day 22)</time_frame>
    <description>Immunogenicity of QIVc to comparator TIVc (For H1N1, H3N2 and B1 strain, the comparison is between QIVc and TIV1c and for B2 i.e. alternate B strain, the comparison is between QIVc and TIV2c) was assessed in terms of percentages of subjects showing seroconversion or significant increase in HI antibody titers, three weeks (day 22) after vaccination with one dose of either QIVc,TIV1c or TIV2c Seroconversion is defined in subjects seronegative at baseline (i.e., HI titer &lt;1:10 at Day 1) as post-vaccination HI titer ≥1:40, and defined in subjects sero-positive at baseline (i.e., HI titer ≥1:10 at Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3. Percentages of Subjects Achieving Seroconversion After One Dose of Either QIVc, TIV1c or TIV2c in 18 to &lt;65 and ≥ 65 Years Age Cohorts</measure>
    <time_frame>Three weeks post vaccination (Day 22)</time_frame>
    <description>Immunogenicity was assessed in terms of percentages of subjects showing seroconversion or significant increase in HI antibody titers, against each vaccine strains, three weeks (day 22) after vaccination with ether QIVc, TIV1c or TIV2c Seroconversion is defined in subjects seronegative at baseline (i.e., HI titer &lt;1:10 at Day 1) as post-vaccination HI titer ≥1:40, and defined in subjects sero-positive at baseline (i.e., HI titer ≥1:10 at Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer.The CBER criterion for 18 to &lt;65 years age group is that the lower bound of the two-sided 95% CI for the percentage of subjects achieving seroconversion for HI antibody should meet or exceed 40% and that for the ≥ 65 years age group should meet or exceed 30%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4. Percentages of Subjects Achieving HI Titer ≥1:40 After One Dose of Either QIVc, TIV1c or TIV2c in 18 to &lt;65 and ≥ 65 Years Age-cohorts</measure>
    <time_frame>Three weeks post vaccination (Day 22)</time_frame>
    <description>Immunogenicity was assessed in terms of percentages of subjects showing HI titer ≥1:40, three weeks (day 22) after vaccination with either QIVc, TIV1c or TIV2c The CBER criterion for 18 to &lt;65 years age group is that the lower bound of the two-sided 95% CI for the percentage of subjects achieving an HI antibody titer ≥ 1:40 should meet or exceed 70% and that for the ≥ 65 years age group should meet or exceed 60%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5.Geometric Mean Ratios (GMR) in Subjects After One Dose of Either QIVc, TIV1c or TIV2c in 18 to ≤60 Years and ≥ 61 Years Age Cohorts</measure>
    <time_frame>Three weeks post vaccination (Day 22)</time_frame>
    <description>Immunogenicity was measured as the geometric mean ratio (GMR). The ratio of post-vaccination to pre-vaccination HI GMTs, three weeks (day 22) after vaccination with either QIVc, TIV1c or TIV2c Committee for Medicinal Products for Human Use (CHMP) criterion for 18 to ≤60 years age group is &gt;2.5 and that for ≥ 61 years age group is &gt;2.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6. Percentages of Subjects Achieving Seroconversion After One Dose of Either QIVc, TIV1c or TIV2c in 18 to ≤60 Years and ≥ 61 Years Age Cohorts</measure>
    <time_frame>Three weeks post vaccination (Day 22)</time_frame>
    <description>Immunogenicity was assessed in terms of percentages of subjects showing seroconversion or significant increase in HI antibody titers, three weeks (day 22) after vaccination with either QIVc, TIV1c or TIV2c Seroconversion is defined in subjects seronegative at baseline (i.e., HI titer &lt;1:10 at Day 1) as post-vaccination HI titer ≥1:40, and defined in subjects sero-positive at baseline (i.e., HI titer ≥1:10 at Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer The CHMP criterion for 18 to ≤60 years age group is that the percentage of subjects achieving seroconversion or significant increase in HI titer is &gt;40% and that for ≥ 61 years age group is &gt;30%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7. Percentages of Subjects Achieving HI Titer ≥1:40 After One Dose of Either QIVc, TIV1c or TIV2c in 18 to ≤60 Years and ≥ 61 Years Age Cohorts</measure>
    <time_frame>Three weeks post vaccination (Day 22)</time_frame>
    <description>Immunogenicity was assessed in terms of percentages of subjects showing HI titer ≥1:40, three weeks (day 22) after vaccination with either QIVc, TIV1c and TIV2c The CHMP criterion for 18 to ≤60 years age group is that the percentage of subjects achieving an HI titer ≥1:40 is &gt;70% and that for ≥ 61 years age group is &gt;60%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>8.Geometric Mean Titres (GMT) in Subjects After Receiving One Dose of Either QIVc, TIV1c Against B2 Strain</measure>
    <time_frame>Three weeks post vaccination (Day 22)</time_frame>
    <description>Immunogenicity of QIVc to TIV1c was assessed by GMT in subjects measured by HI assay, three weeks after vaccination with one dose of either QIVc or TIV1c.
Superiority was established if the upper bound of the two-sided 95% CI for the ratio of GMTs (GMT TIV1c /GMT QIVc) for HI antibody does not exceed the superiority margin of 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9.Percentages of Subjects Achieving Seroconversion After One Dose of Either QIVc, TIV1c Against B2 Strain</measure>
    <time_frame>Three weeks post vaccination (Day 22)</time_frame>
    <description>Immunogenicity of QIVc to TIV1c was assessed in terms of percentages of subjects showing seroconversion or significant increase in HI antibody titers, against influenza strain B2, three weeks (day 22) after vaccination with QIVc or TIV1c Superiority was established if the upper bound of the two-sided 95% CI for the difference between seroconversion rates (% seroconversion TIV1c - % seroconversion QIVc) for HI antibody in ≥ 18 years age group does not exceed the margin of 0 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10.GMT in Subjects After Receiving One Dose of Either QIVc, TIV2c Against B1 Strain</measure>
    <time_frame>Three weeks post vaccination (Day 22)</time_frame>
    <description>Immunogenicity of QIVc to TIV2c was assessed by GMT in subjects measured by HI assay, three weeks after vaccination with one dose of either QIVc or TIV2c.
Superiority was established if the upper bound of the two-sided 95% CI for the ratio of GMTs (GMT TIV2c /GMT QIVc) for HI antibody does not exceed the superiority margin of 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>11.Percentages of Subjects Achieving Seroconversion After One Dose of Either QIVc, TIV2c Against B1 Strain</measure>
    <time_frame>Three weeks post vaccination (Day 22)</time_frame>
    <description>Immunogenicity of QIVc to TIV2c in terms of percentages of subjects showing seroconversion or significant increase in HI antibody titers, against influenza strain B1, three weeks (day 22) after vaccination with QIVc or TIV2c Superiority was established if the upper bound of the two-sided 95% CI for the difference between seroconversion rates (% seroconversion TIV2c - % seroconversion QIVc) for HI antibody in ≥ 18 years age group does not exceed the margin of 0 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12.Number of Subjects Reporting Solicited Adverse Events (AEs) After One Dose of Either QIVc, TIV1c or TIV2c by Overall Age Group</measure>
    <time_frame>Day 1 to 7 post vaccination</time_frame>
    <description>Safety was assessed in terms of number (%) of subjects reporting solicited local and systemic reactions, day 1 to 7 after vaccination with one dose of either four (4) strain inactivated quadrivalent cell based influenza vaccine (QIVc) or trivalent inactivated influenza vaccine (TIV1c or TIV2c)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>13.Number of Subjects Reporting Unsolicited Adverse Events (AEs) After One Dose of Either QIVc, TIV1c or TIV2c by Overall Age Group</measure>
    <time_frame>Day 1 to 181 post vaccination</time_frame>
    <description>Safety was assessed in terms of number (%) of subjects reporting unsolicited AEs (day 1 to 22 after vaccination), serious adverse events (SAEs), medically attended AEs, AEs leading to withdrawal from the study, new onset of chronic diseases (NOCDs), and concomitant medications (day 1 to day 181 post vaccination) after receiving one dose of either four (4) strain inactivated quadrivalent cell based influenza vaccine (QIVc) or trivalent inactivated influenza vaccine (TIV1c or TIV2c)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2680</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>QIVc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Influenza vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIV1c</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Influenza vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIV2c</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Influenza vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>QIVc</intervention_name>
    <description>Novartis Investigational Quadrivalent Vaccine</description>
    <arm_group_label>QIVc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TIV1c</intervention_name>
    <description>Licensed Influenza Vaccine</description>
    <arm_group_label>TIV1c</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TIV2c</intervention_name>
    <description>Novartis Investigational Vaccine</description>
    <arm_group_label>TIV2c</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ages 18 years and older.

          2. Individuals who give written informed consent, who can comply with study procedures,
             and who are available for follow-up.

        Exclusion Criteria:

          1. Individuals recently vaccinated against influenza

          2. Subjects with contraindications to receive influenza vaccine

          3. Please contact the site for additional eligibility criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mishawaka</city>
        <state>Indiana</state>
        <zip>46545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dakota Dunes</city>
        <state>South Dakota</state>
        <zip>57049</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2013</study_first_submitted>
  <study_first_submitted_qc>November 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <results_first_submitted>February 27, 2015</results_first_submitted>
  <results_first_submitted_qc>November 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 10, 2015</results_first_posted>
  <last_update_submitted>November 2, 2015</last_update_submitted>
  <last_update_submitted_qc>November 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Influenza vaccine</keyword>
  <keyword>Novartis</keyword>
  <keyword>Adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from 40 centers in US</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the trial</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>QIVc (≥18 Years)</title>
          <description>Subjects received one dose of cell derived quadrivalent influenza vaccine (QIVc)</description>
        </group>
        <group group_id="P2">
          <title>TIV1c (≥18 Years)</title>
          <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV1c (H1N1,H3N2, B1) recommended for 2013-2014 season</description>
        </group>
        <group group_id="P3">
          <title>TIV2c (≥18 Years)</title>
          <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV2c that contains an alternate B strain compared to what is recommended for 2013-2014</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1335"/>
                <participants group_id="P2" count="676"/>
                <participants group_id="P3" count="669"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1285"/>
                <participants group_id="P2" count="652"/>
                <participants group_id="P3" count="648"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>ADMINISTRATIVE REASON</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>OTHER</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>QIVc (≥18 Years)</title>
          <description>Subjects received one dose of cell derived quadrivalent influenza vaccine (QIVc)</description>
        </group>
        <group group_id="B2">
          <title>TIV1c (≥18 Years)</title>
          <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV1c (H1N1,H3N2, B1) recommended for 2013-2014 season</description>
        </group>
        <group group_id="B3">
          <title>TIV2c (≥18 Years)</title>
          <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV2c that contains an alternate B strain compared to what is recommended for 2013-2014</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1335"/>
            <count group_id="B2" value="676"/>
            <count group_id="B3" value="669"/>
            <count group_id="B4" value="2680"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.4" spread="17.8"/>
                    <measurement group_id="B2" value="57.2" spread="18.0"/>
                    <measurement group_id="B3" value="57.1" spread="18.1"/>
                    <measurement group_id="B4" value="57.3" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="732"/>
                    <measurement group_id="B2" value="392"/>
                    <measurement group_id="B3" value="392"/>
                    <measurement group_id="B4" value="1516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="603"/>
                    <measurement group_id="B2" value="284"/>
                    <measurement group_id="B3" value="277"/>
                    <measurement group_id="B4" value="1164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>1.Geometric Mean Titres (GMT) in Subjects After Receiving One Dose of Either QIVc, TIV1c or TIV2c</title>
        <description>Immunogenicity of QIVc to comparator TIVc (For H1N1, H3N2 and B1 strain, the comparison is between QIVc and TIV1c and for B2 i.e. alternate B strain, the comparison is between QIVc and TIV2c) was assessed in terms of GMT in subjects measured by hemagglutination inhibition (HI) assay, three weeks after vaccination with one dose of either QIVc or TIV1c and TIV2c.
Non-inferiority was established if the upper bound of the two-sided 95% confidence interval (CI) for the ratio of GMTs (GMT TIV1c or TIV2c /GMT QIVc) for HI antibody does not exceed the non-inferiority margin of 1.5.</description>
        <time_frame>Three weeks post vaccination (Day 22)</time_frame>
        <population>Analysis was done on Per Protocol (PP) Population i.e. all subjects in the Full Analysis Set (FAS) efficacy/immunogenicity population correctly receive the vaccine, have no major protocol deviations leading to exclusion as defined prior to unblinding/analysis and are not excluded due to other reasons defined prior to unblinding or analysis</population>
        <group_list>
          <group group_id="O1">
            <title>QIVc (≥18 Years)</title>
            <description>Subjects received one dose of cell derived quadrivalent influenza vaccine (QIVc)</description>
          </group>
          <group group_id="O2">
            <title>TIV1c (≥18 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV1c (H1N1, H3N2, B1) recommended for 2013-2014 season</description>
          </group>
          <group group_id="O3">
            <title>TIV2c (≥18 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV2c that contains an alternate B strain compared to what is recommended for 2013-2014</description>
          </group>
        </group_list>
        <measure>
          <title>1.Geometric Mean Titres (GMT) in Subjects After Receiving One Dose of Either QIVc, TIV1c or TIV2c</title>
          <description>Immunogenicity of QIVc to comparator TIVc (For H1N1, H3N2 and B1 strain, the comparison is between QIVc and TIV1c and for B2 i.e. alternate B strain, the comparison is between QIVc and TIV2c) was assessed in terms of GMT in subjects measured by hemagglutination inhibition (HI) assay, three weeks after vaccination with one dose of either QIVc or TIV1c and TIV2c.
Non-inferiority was established if the upper bound of the two-sided 95% confidence interval (CI) for the ratio of GMTs (GMT TIV1c or TIV2c /GMT QIVc) for HI antibody does not exceed the non-inferiority margin of 1.5.</description>
          <population>Analysis was done on Per Protocol (PP) Population i.e. all subjects in the Full Analysis Set (FAS) efficacy/immunogenicity population correctly receive the vaccine, have no major protocol deviations leading to exclusion as defined prior to unblinding/analysis and are not excluded due to other reasons defined prior to unblinding or analysis</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1335"/>
                <count group_id="O2" value="676"/>
                <count group_id="O3" value="669"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1: Day 1(N=1250,635,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7" lower_limit="56.0" upper_limit="65.9"/>
                    <measurement group_id="O2" value="59.6" lower_limit="53.0" upper_limit="67.0"/>
                    <measurement group_id="O3" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1: Day 22(N=1250,635,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302.8" lower_limit="281.8" upper_limit="325.5"/>
                    <measurement group_id="O2" value="298.9" lower_limit="270.3" upper_limit="330.5"/>
                    <measurement group_id="O3" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2: Day 1(N=1250,635,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.5" lower_limit="112.7" upper_limit="133.1"/>
                    <measurement group_id="O2" value="128.1" lower_limit="113.6" upper_limit="144.6"/>
                    <measurement group_id="O3" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2: Day 22(N=1250,635,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="372.3" lower_limit="349.2" upper_limit="396.9"/>
                    <measurement group_id="O2" value="378.4" lower_limit="345.1" upper_limit="414.8"/>
                    <measurement group_id="O3" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B1:Day 1(N=1250,635,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3" lower_limit="42.6" upper_limit="48.1"/>
                    <measurement group_id="O2" value="43.8" lower_limit="40.2" upper_limit="47.7"/>
                    <measurement group_id="O3" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B1:Day 22(N=1250,635,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.2" lower_limit="125.3" upper_limit="141.7"/>
                    <measurement group_id="O2" value="115.6" lower_limit="106.4" upper_limit="125.6"/>
                    <measurement group_id="O3" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B2:Day 1(N=1250,NA,639)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2" lower_limit="56.0" upper_limit="62.7"/>
                    <measurement group_id="O2" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O3" value="58.0" lower_limit="53.4" upper_limit="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B2:Day 22(N=1250,NA,639)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.2" lower_limit="167.6" upper_limit="187.5"/>
                    <measurement group_id="O2" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O3" value="164.0" lower_limit="151.4" upper_limit="177.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of QIVc to TIV1c, assessed in terms of ratios of GMT against influenza strain H1N1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the upper bound of the two-sided 95% confidence interval (CI) for the ratio of GMTs (GMT TIV1c/GMT QIVc) for HI antibody does not exceed the non-inferiority margin of 1.5</non_inferiority_desc>
            <param_type>Ratios of GMT</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of QIVc to TIV1c, assessed in terms of ratios of GMT against influenza strain H3N2</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the upper bound of the two-sided 95% confidence interval (CI) for the ratio of GMTs (GMT TIV1c/GMT QIVc) for HI antibody does not exceed the non-inferiority margin of 1.5</non_inferiority_desc>
            <param_type>Ratios of GMT</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of QIVc to TIV1c, assessed in terms of ratios of GMT against influenza strain B1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the upper bound of the two-sided 95% confidence interval (CI) for the ratio of GMTs (GMT TIV1c/GMT QIVc) for HI antibody does not exceed the non-inferiority margin of 1.5</non_inferiority_desc>
            <param_type>Ratios of GMT</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of QIVc to TIV2c, assessed in terms of ratios of GMT against influenza strain B2</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the upper bound of the two-sided 95% confidence interval (CI) for the ratio of GMTs (GMT TIV2c/GMT QIVc) for HI antibody does not exceed the non-inferiority margin of 1.5</non_inferiority_desc>
            <param_type>Ratios of GMT</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>2. Percentages of Subjects Achieving Seroconversion After One Dose of Either QIVc, TIV1c or TIV2c</title>
        <description>Immunogenicity of QIVc to comparator TIVc (For H1N1, H3N2 and B1 strain, the comparison is between QIVc and TIV1c and for B2 i.e. alternate B strain, the comparison is between QIVc and TIV2c) was assessed in terms of percentages of subjects showing seroconversion or significant increase in HI antibody titers, three weeks (day 22) after vaccination with one dose of either QIVc,TIV1c or TIV2c Seroconversion is defined in subjects seronegative at baseline (i.e., HI titer &lt;1:10 at Day 1) as post-vaccination HI titer ≥1:40, and defined in subjects sero-positive at baseline (i.e., HI titer ≥1:10 at Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer</description>
        <time_frame>Three weeks post vaccination (Day 22)</time_frame>
        <population>Analysis was done on PP population</population>
        <group_list>
          <group group_id="O1">
            <title>QIVc (≥18 Years)</title>
            <description>Subjects received one dose of cell derived quadrivalent influenza vaccine (QIVc)</description>
          </group>
          <group group_id="O2">
            <title>TIV1c (≥18 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV1c (H1N1, H3N2, B1) recommended for 2013-2014 season</description>
          </group>
          <group group_id="O3">
            <title>TIV2c (≥18 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV2c that contains an alternate B strain compared to what is recommended for 2013-2014</description>
          </group>
        </group_list>
        <measure>
          <title>2. Percentages of Subjects Achieving Seroconversion After One Dose of Either QIVc, TIV1c or TIV2c</title>
          <description>Immunogenicity of QIVc to comparator TIVc (For H1N1, H3N2 and B1 strain, the comparison is between QIVc and TIV1c and for B2 i.e. alternate B strain, the comparison is between QIVc and TIV2c) was assessed in terms of percentages of subjects showing seroconversion or significant increase in HI antibody titers, three weeks (day 22) after vaccination with one dose of either QIVc,TIV1c or TIV2c Seroconversion is defined in subjects seronegative at baseline (i.e., HI titer &lt;1:10 at Day 1) as post-vaccination HI titer ≥1:40, and defined in subjects sero-positive at baseline (i.e., HI titer ≥1:10 at Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer</description>
          <population>Analysis was done on PP population</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1335"/>
                <count group_id="O2" value="676"/>
                <count group_id="O3" value="669"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1: Day 22(N=1250, 635,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" lower_limit="46.4" upper_limit="52.0"/>
                    <measurement group_id="O2" value="48.7" lower_limit="44.7" upper_limit="52.6"/>
                    <measurement group_id="O3" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2: Day 22(N=1250, 635,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" lower_limit="35.6" upper_limit="41.1"/>
                    <measurement group_id="O2" value="35.6" lower_limit="31.9" upper_limit="39.5"/>
                    <measurement group_id="O3" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B1: Day 22(N=1250, 635,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6" lower_limit="33.9" upper_limit="39.3"/>
                    <measurement group_id="O2" value="34.8" lower_limit="31.1" upper_limit="38.7"/>
                    <measurement group_id="O3" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B2: Day 22(N=1250,NA, 639)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" lower_limit="37.0" upper_limit="42.5"/>
                    <measurement group_id="O2" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O3" value="35.4" lower_limit="31.7" upper_limit="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of QIVc to TIV1c in terms of differences in seroconversion rates against influenza strain H1N1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the upper bound of the two-sided 95% CI for the difference between seroconversion rates (% seroconversion TIV1c – % seroconversion QIVc) for HI antibody does not exceed the margin of 10%</non_inferiority_desc>
            <param_type>Difference between seroconversion rates</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.3</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of QIVc to TIV1c in terms of differences in seroconversion rates against influenza strainH3N2</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the upper bound of the two-sided 95% CI for the difference between seroconversion rates (% seroconversion TIV1c – % seroconversion QIVc) for HI antibody does not exceed the margin of 10%</non_inferiority_desc>
            <param_type>Difference between seroconversion rates</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.2</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of QIVc to TIV1c in terms of differences in seroconversion rates against influenza strain B1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the upper bound of the two-sided 95% CI for the difference between seroconversion rates (% seroconversion TIV1c – % seroconversion QIVc) for HI antibody does not exceed the margin of 10%</non_inferiority_desc>
            <param_type>Difference between seroconversion rates</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.2</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of immune responses of QIVc to TIV2c in terms of differences in seroconversion rates against influenza strain B2</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was established if the upper bound of the two-sided 95% CI for the difference between seroconversion rates (% seroconversion TIV2c – % seroconversion QIVc) for HI antibody does not exceed the margin of 10%</non_inferiority_desc>
            <param_type>Difference between seroconversion rates</param_type>
            <param_value>-4.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.9</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>3. Percentages of Subjects Achieving Seroconversion After One Dose of Either QIVc, TIV1c or TIV2c in 18 to &lt;65 and ≥ 65 Years Age Cohorts</title>
        <description>Immunogenicity was assessed in terms of percentages of subjects showing seroconversion or significant increase in HI antibody titers, against each vaccine strains, three weeks (day 22) after vaccination with ether QIVc, TIV1c or TIV2c Seroconversion is defined in subjects seronegative at baseline (i.e., HI titer &lt;1:10 at Day 1) as post-vaccination HI titer ≥1:40, and defined in subjects sero-positive at baseline (i.e., HI titer ≥1:10 at Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer.The CBER criterion for 18 to &lt;65 years age group is that the lower bound of the two-sided 95% CI for the percentage of subjects achieving seroconversion for HI antibody should meet or exceed 40% and that for the ≥ 65 years age group should meet or exceed 30%</description>
        <time_frame>Three weeks post vaccination (Day 22)</time_frame>
        <population>Analysis was done on FAS immunogenicity set i.e. all subjects in the enrolled set who receive the study vaccination and provide immunogenicity data at visit 1 and visit 2</population>
        <group_list>
          <group group_id="O1">
            <title>QIVc (18 to &lt;65 Years)</title>
            <description>Subjects received one dose of cell derived quadrivalent influenza vaccine (QIVc)</description>
          </group>
          <group group_id="O2">
            <title>QIVc (≥ 65 Years)</title>
            <description>Subjects received one dose of cell derived quadrivalent influenza vaccine (QIVc)</description>
          </group>
          <group group_id="O3">
            <title>TIV1c (18 to &lt;65 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV1c (H1N1, H3N2, B1) recommended for 2013- 2014 season</description>
          </group>
          <group group_id="O4">
            <title>TIV1c (≥ 65 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV1c (H1N1,H3N2, B1)recommended for 2013-2014 season</description>
          </group>
          <group group_id="O5">
            <title>TIV2c (18 to &lt;65 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV2c that contains an alternate B strain compared to what is recommended for 2013-2014</description>
          </group>
          <group group_id="O6">
            <title>TIV2c (≥ 65 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV2c that contains an alternate B strain compared to what is recommended for 2013-2014</description>
          </group>
        </group_list>
        <measure>
          <title>3. Percentages of Subjects Achieving Seroconversion After One Dose of Either QIVc, TIV1c or TIV2c in 18 to &lt;65 and ≥ 65 Years Age Cohorts</title>
          <description>Immunogenicity was assessed in terms of percentages of subjects showing seroconversion or significant increase in HI antibody titers, against each vaccine strains, three weeks (day 22) after vaccination with ether QIVc, TIV1c or TIV2c Seroconversion is defined in subjects seronegative at baseline (i.e., HI titer &lt;1:10 at Day 1) as post-vaccination HI titer ≥1:40, and defined in subjects sero-positive at baseline (i.e., HI titer ≥1:10 at Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer.The CBER criterion for 18 to &lt;65 years age group is that the lower bound of the two-sided 95% CI for the percentage of subjects achieving seroconversion for HI antibody should meet or exceed 40% and that for the ≥ 65 years age group should meet or exceed 30%</description>
          <population>Analysis was done on FAS immunogenicity set i.e. all subjects in the enrolled set who receive the study vaccination and provide immunogenicity data at visit 1 and visit 2</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="661"/>
                <count group_id="O2" value="650"/>
                <count group_id="O3" value="328"/>
                <count group_id="O4" value="336"/>
                <count group_id="O5" value="326"/>
                <count group_id="O6" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1: Day 22(N=661, 650, 328, 336,NA,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.1" lower_limit="59.3" upper_limit="66.8"/>
                    <measurement group_id="O2" value="34.5" lower_limit="30.8" upper_limit="38.3"/>
                    <measurement group_id="O3" value="60.4" lower_limit="54.8" upper_limit="65.7"/>
                    <measurement group_id="O4" value="36.9" lower_limit="31.7" upper_limit="42.3"/>
                    <measurement group_id="O5" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O6" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2: Day 22(N=661, 650, 328, 336,NA,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" lower_limit="45.3" upper_limit="53.1"/>
                    <measurement group_id="O2" value="27.2" lower_limit="23.8" upper_limit="30.8"/>
                    <measurement group_id="O3" value="47.3" lower_limit="41.7" upper_limit="52.8"/>
                    <measurement group_id="O4" value="24.7" lower_limit="20.2" upper_limit="29.7"/>
                    <measurement group_id="O5" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O6" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B1: Day 22(N=661, 650, 328, 336,NA,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.0" lower_limit="48.2" upper_limit="55.9"/>
                    <measurement group_id="O2" value="20.9" lower_limit="17.9" upper_limit="24.3"/>
                    <measurement group_id="O3" value="50.3" lower_limit="44.8" upper_limit="55.8"/>
                    <measurement group_id="O4" value="19.3" lower_limit="15.3" upper_limit="24.0"/>
                    <measurement group_id="O5" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O6" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B2: Day 22(N=661, 650,NA,NA, 326, 332)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8" lower_limit="48.9" upper_limit="56.7"/>
                    <measurement group_id="O2" value="26.3" lower_limit="23.0" upper_limit="29.9"/>
                    <measurement group_id="O3" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O4" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O5" value="50.3" lower_limit="44.7" upper_limit="55.9"/>
                    <measurement group_id="O6" value="20.8" lower_limit="16.5" upper_limit="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>4. Percentages of Subjects Achieving HI Titer ≥1:40 After One Dose of Either QIVc, TIV1c or TIV2c in 18 to &lt;65 and ≥ 65 Years Age-cohorts</title>
        <description>Immunogenicity was assessed in terms of percentages of subjects showing HI titer ≥1:40, three weeks (day 22) after vaccination with either QIVc, TIV1c or TIV2c The CBER criterion for 18 to &lt;65 years age group is that the lower bound of the two-sided 95% CI for the percentage of subjects achieving an HI antibody titer ≥ 1:40 should meet or exceed 70% and that for the ≥ 65 years age group should meet or exceed 60%</description>
        <time_frame>Three weeks post vaccination (Day 22)</time_frame>
        <population>Analysis was done on FAS immunogenicity set.</population>
        <group_list>
          <group group_id="O1">
            <title>QIVc (18 to &lt;65 Years)</title>
            <description>Subjects received one dose of cell derived quadrivalent influenza vaccine (QIVc)</description>
          </group>
          <group group_id="O2">
            <title>QIVc (≥ 65 Years)</title>
            <description>Subjects received one dose of cell derived quadrivalent influenza vaccine (QIVc)</description>
          </group>
          <group group_id="O3">
            <title>TIV1c (18 to &lt;65 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV1c (H1N1,H3N2, B1) recommended for 2013-2014 season</description>
          </group>
          <group group_id="O4">
            <title>TIV1c (≥ 65 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV1c (H1N1,H3N2, B1) recommended for 2013-2014 season</description>
          </group>
          <group group_id="O5">
            <title>TIV2c (18 to &lt;65 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV2c that contains an alternate B strain compared to what is recommended for 2013-2014</description>
          </group>
          <group group_id="O6">
            <title>TIV2c (≥ 65 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV2c that contains an alternate B strain compared to what is recommended for 2013-2014</description>
          </group>
        </group_list>
        <measure>
          <title>4. Percentages of Subjects Achieving HI Titer ≥1:40 After One Dose of Either QIVc, TIV1c or TIV2c in 18 to &lt;65 and ≥ 65 Years Age-cohorts</title>
          <description>Immunogenicity was assessed in terms of percentages of subjects showing HI titer ≥1:40, three weeks (day 22) after vaccination with either QIVc, TIV1c or TIV2c The CBER criterion for 18 to &lt;65 years age group is that the lower bound of the two-sided 95% CI for the percentage of subjects achieving an HI antibody titer ≥ 1:40 should meet or exceed 70% and that for the ≥ 65 years age group should meet or exceed 60%</description>
          <population>Analysis was done on FAS immunogenicity set.</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="661"/>
                <count group_id="O2" value="650"/>
                <count group_id="O3" value="328"/>
                <count group_id="O4" value="336"/>
                <count group_id="O5" value="326"/>
                <count group_id="O6" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1: Day 1(N=661, 650, 328, 336,NA,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.8" lower_limit="60.0" upper_limit="67.5"/>
                    <measurement group_id="O2" value="79.2" lower_limit="75.9" upper_limit="82.3"/>
                    <measurement group_id="O3" value="64.6" lower_limit="59.2" upper_limit="69.8"/>
                    <measurement group_id="O4" value="76.5" lower_limit="71.6" upper_limit="80.9"/>
                    <measurement group_id="O5" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O6" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1: Day 22(N=661, 650, 328, 336,NA,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" lower_limit="97.2" upper_limit="99.3"/>
                    <measurement group_id="O2" value="94.3" lower_limit="92.2" upper_limit="96.0"/>
                    <measurement group_id="O3" value="97.0" lower_limit="94.5" upper_limit="98.5"/>
                    <measurement group_id="O4" value="96.1" lower_limit="93.5" upper_limit="97.9"/>
                    <measurement group_id="O5" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O6" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2: Day 1(N=661, 650, 328, 336,NA,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.2" lower_limit="74.9" upper_limit="81.3"/>
                    <measurement group_id="O2" value="89.5" lower_limit="86.9" upper_limit="91.8"/>
                    <measurement group_id="O3" value="80.5" lower_limit="75.8" upper_limit="84.6"/>
                    <measurement group_id="O4" value="88.4" lower_limit="84.5" upper_limit="91.6"/>
                    <measurement group_id="O5" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O6" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2: Day 22(N=661, 650, 328, 336,NA,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" lower_limit="97.4" upper_limit="99.4"/>
                    <measurement group_id="O2" value="98.3" lower_limit="97.0" upper_limit="99.2"/>
                    <measurement group_id="O3" value="99.1" lower_limit="97.4" upper_limit="99.8"/>
                    <measurement group_id="O4" value="98.2" lower_limit="96.2" upper_limit="99.3"/>
                    <measurement group_id="O5" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O6" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B1: Day 1(N=661, 650, 328, 336,NA,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6" lower_limit="60.8" upper_limit="68.2"/>
                    <measurement group_id="O2" value="72.3" lower_limit="68.7" upper_limit="75.7"/>
                    <measurement group_id="O3" value="62.8" lower_limit="57.3" upper_limit="68.1"/>
                    <measurement group_id="O4" value="67.9" lower_limit="62.6" upper_limit="72.8"/>
                    <measurement group_id="O5" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O6" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B1: Day 22(N=661, 650, 328, 336,NA,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.6" lower_limit="93.8" upper_limit="97.0"/>
                    <measurement group_id="O2" value="92.2" lower_limit="89.8" upper_limit="94.1"/>
                    <measurement group_id="O3" value="95.7" lower_limit="92.9" upper_limit="97.6"/>
                    <measurement group_id="O4" value="87.8" lower_limit="83.8" upper_limit="91.1"/>
                    <measurement group_id="O5" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O6" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B2: Day 1(N=661, 650,NA,NA, 326, 332)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9" lower_limit="71.4" upper_limit="78.2"/>
                    <measurement group_id="O2" value="81.2" lower_limit="78.0" upper_limit="84.2"/>
                    <measurement group_id="O3" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O4" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O5" value="73.3" lower_limit="68.2" upper_limit="78.0"/>
                    <measurement group_id="O6" value="81.0" lower_limit="76.4" upper_limit="85.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B2: Day 22(N=661, 650,NA,NA, 326, 332)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.1" lower_limit="98.0" upper_limit="99.7"/>
                    <measurement group_id="O2" value="96.2" lower_limit="94.4" upper_limit="97.5"/>
                    <measurement group_id="O3" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O4" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O5" value="98.8" lower_limit="96.9" upper_limit="99.7"/>
                    <measurement group_id="O6" value="95.2" lower_limit="92.3" upper_limit="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5.Geometric Mean Ratios (GMR) in Subjects After One Dose of Either QIVc, TIV1c or TIV2c in 18 to ≤60 Years and ≥ 61 Years Age Cohorts</title>
        <description>Immunogenicity was measured as the geometric mean ratio (GMR). The ratio of post-vaccination to pre-vaccination HI GMTs, three weeks (day 22) after vaccination with either QIVc, TIV1c or TIV2c Committee for Medicinal Products for Human Use (CHMP) criterion for 18 to ≤60 years age group is &gt;2.5 and that for ≥ 61 years age group is &gt;2.0</description>
        <time_frame>Three weeks post vaccination (Day 22)</time_frame>
        <population>Analysis was done on FAS immunogenicity set.</population>
        <group_list>
          <group group_id="O1">
            <title>QIVc (18 to ≤60 Years)</title>
            <description>Subjects received one dose of cell derived quadrivalent influenza vaccine (QIVc)</description>
          </group>
          <group group_id="O2">
            <title>QIVc (≥ 61 Years)</title>
            <description>Subjects received one dose of cell derived quadrivalent influenza vaccine (QIVc)</description>
          </group>
          <group group_id="O3">
            <title>TIV1c (18 to ≤60 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV1c (H1N1,H3N2, B1) recommended for 2013- 2014 season</description>
          </group>
          <group group_id="O4">
            <title>TIV1c (≥ 61 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV1c (H1N1,H3N2, B1) recommended for 2013- 2014 season</description>
          </group>
          <group group_id="O5">
            <title>TIV2c (18 to ≤60 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV2c that contains an alternate B strain compared to what is recommended for 2013-2014</description>
          </group>
          <group group_id="O6">
            <title>TIV2c (≥ 61 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV2c that contains an alternate B strain compared to what is recommended for 2013-2014</description>
          </group>
        </group_list>
        <measure>
          <title>5.Geometric Mean Ratios (GMR) in Subjects After One Dose of Either QIVc, TIV1c or TIV2c in 18 to ≤60 Years and ≥ 61 Years Age Cohorts</title>
          <description>Immunogenicity was measured as the geometric mean ratio (GMR). The ratio of post-vaccination to pre-vaccination HI GMTs, three weeks (day 22) after vaccination with either QIVc, TIV1c or TIV2c Committee for Medicinal Products for Human Use (CHMP) criterion for 18 to ≤60 years age group is &gt;2.5 and that for ≥ 61 years age group is &gt;2.0</description>
          <population>Analysis was done on FAS immunogenicity set.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="606"/>
                <count group_id="O2" value="705"/>
                <count group_id="O3" value="306"/>
                <count group_id="O4" value="358"/>
                <count group_id="O5" value="297"/>
                <count group_id="O6" value="361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1(Day 22/Day1)(N=606,705,306,358,NA,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" lower_limit="8.0" upper_limit="10.6"/>
                    <measurement group_id="O2" value="3.0" lower_limit="2.7" upper_limit="3.2"/>
                    <measurement group_id="O3" value="9.1" lower_limit="7.5" upper_limit="11.1"/>
                    <measurement group_id="O4" value="3.0" lower_limit="2.7" upper_limit="3.4"/>
                    <measurement group_id="O5" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O6" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 22/Day1)(N=606,705,306,358,NA,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="3.8" upper_limit="4.7"/>
                    <measurement group_id="O2" value="2.3" lower_limit="2.1" upper_limit="2.5"/>
                    <measurement group_id="O3" value="4.2" lower_limit="3.6" upper_limit="4.9"/>
                    <measurement group_id="O4" value="2.2" lower_limit="2.0" upper_limit="2.5"/>
                    <measurement group_id="O5" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O6" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B1 (Day 22/Day1)(N=606,705,306,358,NA,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="4.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.9" upper_limit="2.2"/>
                    <measurement group_id="O3" value="4.1" lower_limit="3.5" upper_limit="4.8"/>
                    <measurement group_id="O4" value="1.8" lower_limit="1.7" upper_limit="2.0"/>
                    <measurement group_id="O5" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O6" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B2 (Day 22/Day1)(N=606,705,NA,NA,297,361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="3.9" upper_limit="4.8"/>
                    <measurement group_id="O2" value="2.2" lower_limit="2.0" upper_limit="2.3"/>
                    <measurement group_id="O3" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O4" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O5" value="4.1" lower_limit="3.5" upper_limit="4.7"/>
                    <measurement group_id="O6" value="2.1" lower_limit="1.9" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6. Percentages of Subjects Achieving Seroconversion After One Dose of Either QIVc, TIV1c or TIV2c in 18 to ≤60 Years and ≥ 61 Years Age Cohorts</title>
        <description>Immunogenicity was assessed in terms of percentages of subjects showing seroconversion or significant increase in HI antibody titers, three weeks (day 22) after vaccination with either QIVc, TIV1c or TIV2c Seroconversion is defined in subjects seronegative at baseline (i.e., HI titer &lt;1:10 at Day 1) as post-vaccination HI titer ≥1:40, and defined in subjects sero-positive at baseline (i.e., HI titer ≥1:10 at Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer The CHMP criterion for 18 to ≤60 years age group is that the percentage of subjects achieving seroconversion or significant increase in HI titer is &gt;40% and that for ≥ 61 years age group is &gt;30%</description>
        <time_frame>Three weeks post vaccination (Day 22)</time_frame>
        <population>Analysis was done on FAS immunogenicity set.</population>
        <group_list>
          <group group_id="O1">
            <title>QIVc (18 to ≤60 Years)</title>
            <description>Subjects received one dose of cell derived quadrivalent influenza vaccine (QIVc)</description>
          </group>
          <group group_id="O2">
            <title>QIVc (≥ 61 Years)</title>
            <description>Subjects received one dose of cell derived quadrivalent influenza vaccine (QIVc)</description>
          </group>
          <group group_id="O3">
            <title>TIV1c (18 to ≤60 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV1c (H1N1,H3N2, B1) recommended for 2013- 2014 season</description>
          </group>
          <group group_id="O4">
            <title>TIV1c (≥ 61 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV1c (H1N1,H3N2, B1) recommended for 2013- 2014 season</description>
          </group>
          <group group_id="O5">
            <title>TIV2c (18 to ≤60 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV2c that contains an alternate B strain compared to what is recommended for 2013-2014</description>
          </group>
          <group group_id="O6">
            <title>TIV2c (≥ 61 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV2c that contains an alternate B strain compared to what is recommended for 2013-2014</description>
          </group>
        </group_list>
        <measure>
          <title>6. Percentages of Subjects Achieving Seroconversion After One Dose of Either QIVc, TIV1c or TIV2c in 18 to ≤60 Years and ≥ 61 Years Age Cohorts</title>
          <description>Immunogenicity was assessed in terms of percentages of subjects showing seroconversion or significant increase in HI antibody titers, three weeks (day 22) after vaccination with either QIVc, TIV1c or TIV2c Seroconversion is defined in subjects seronegative at baseline (i.e., HI titer &lt;1:10 at Day 1) as post-vaccination HI titer ≥1:40, and defined in subjects sero-positive at baseline (i.e., HI titer ≥1:10 at Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer The CHMP criterion for 18 to ≤60 years age group is that the percentage of subjects achieving seroconversion or significant increase in HI titer is &gt;40% and that for ≥ 61 years age group is &gt;30%</description>
          <population>Analysis was done on FAS immunogenicity set.</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="606"/>
                <count group_id="O2" value="705"/>
                <count group_id="O3" value="306"/>
                <count group_id="O4" value="358"/>
                <count group_id="O5" value="297"/>
                <count group_id="O6" value="361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1: Day 22(N=606,705,306,358,NA,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.5" lower_limit="59.6" upper_limit="67.4"/>
                    <measurement group_id="O2" value="36.3" lower_limit="32.8" upper_limit="40.4"/>
                    <measurement group_id="O3" value="62.1" lower_limit="56.4" upper_limit="67.6"/>
                    <measurement group_id="O4" value="36.9" lower_limit="31.9" upper_limit="42.1"/>
                    <measurement group_id="O5" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O6" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2: Day 22(N=606,705,306,358,NA,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.8" lower_limit="45.8" upper_limit="53.9"/>
                    <measurement group_id="O2" value="28.4" lower_limit="25.1" upper_limit="31.9"/>
                    <measurement group_id="O3" value="48.7" lower_limit="43.0" upper_limit="54.4"/>
                    <measurement group_id="O4" value="24.9" lower_limit="20.5" upper_limit="29.7"/>
                    <measurement group_id="O5" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O6" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B1: Day 22(N=606,705,306,358,NA,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" lower_limit="49.2" upper_limit="57.3"/>
                    <measurement group_id="O2" value="22.3" lower_limit="19.2" upper_limit="25.5"/>
                    <measurement group_id="O3" value="52.3" lower_limit="46.5" upper_limit="58.0"/>
                    <measurement group_id="O4" value="19.6" lower_limit="15.6" upper_limit="24.0"/>
                    <measurement group_id="O5" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O6" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B2: Day 22(N=606,705,NA,NA,297,361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8" lower_limit="49.7" upper_limit="57.8"/>
                    <measurement group_id="O2" value="27.5" lower_limit="24.3" upper_limit="31.0"/>
                    <measurement group_id="O3" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O4" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O5" value="51.2" lower_limit="45.3" upper_limit="57.0"/>
                    <measurement group_id="O6" value="22.4" lower_limit="18.2" upper_limit="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>7. Percentages of Subjects Achieving HI Titer ≥1:40 After One Dose of Either QIVc, TIV1c or TIV2c in 18 to ≤60 Years and ≥ 61 Years Age Cohorts</title>
        <description>Immunogenicity was assessed in terms of percentages of subjects showing HI titer ≥1:40, three weeks (day 22) after vaccination with either QIVc, TIV1c and TIV2c The CHMP criterion for 18 to ≤60 years age group is that the percentage of subjects achieving an HI titer ≥1:40 is &gt;70% and that for ≥ 61 years age group is &gt;60%</description>
        <time_frame>Three weeks post vaccination (Day 22)</time_frame>
        <population>Analysis was done on FAS immunogenicity set.</population>
        <group_list>
          <group group_id="O1">
            <title>QIVc (18 to ≤60 Years)</title>
            <description>Subjects received one dose of cell derived quadrivalent influenza vaccine (QIVc)</description>
          </group>
          <group group_id="O2">
            <title>QIVc (≥ 61 Years)</title>
            <description>Subjects received one dose of cell derived quadrivalent influenza vaccine (QIVc)</description>
          </group>
          <group group_id="O3">
            <title>TIV1c (18 to ≤60 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV1c (H1N1,H3N2, B1) recommended for 2013- 2014 season</description>
          </group>
          <group group_id="O4">
            <title>TIV1c (≥ 61 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV1c (H1N1,H3N2, B1) recommended for 2013- 2014 season</description>
          </group>
          <group group_id="O5">
            <title>TIV2c (18 to ≤60 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV2c that contains an alternate B strain compared to what is recommended for 2013-2014</description>
          </group>
          <group group_id="O6">
            <title>TIV2c (≥ 61 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV2c that contains an alternate B strain compared to what is recommended for 2013-2014</description>
          </group>
        </group_list>
        <measure>
          <title>7. Percentages of Subjects Achieving HI Titer ≥1:40 After One Dose of Either QIVc, TIV1c or TIV2c in 18 to ≤60 Years and ≥ 61 Years Age Cohorts</title>
          <description>Immunogenicity was assessed in terms of percentages of subjects showing HI titer ≥1:40, three weeks (day 22) after vaccination with either QIVc, TIV1c and TIV2c The CHMP criterion for 18 to ≤60 years age group is that the percentage of subjects achieving an HI titer ≥1:40 is &gt;70% and that for ≥ 61 years age group is &gt;60%</description>
          <population>Analysis was done on FAS immunogenicity set.</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="606"/>
                <count group_id="O2" value="705"/>
                <count group_id="O3" value="306"/>
                <count group_id="O4" value="358"/>
                <count group_id="O5" value="297"/>
                <count group_id="O6" value="361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1: Day 1(N=606,705,306,358,NA,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.4" lower_limit="60.4" upper_limit="68.2"/>
                    <measurement group_id="O2" value="77.6" lower_limit="74.3" upper_limit="80.6"/>
                    <measurement group_id="O3" value="65.0" lower_limit="59.4" upper_limit="70.4"/>
                    <measurement group_id="O4" value="75.4" lower_limit="70.6" upper_limit="79.8"/>
                    <measurement group_id="O5" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="0" upper_limit="0">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1: Day 22(N=606,705,306,358,NA,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" lower_limit="97.0" upper_limit="99.2"/>
                    <measurement group_id="O2" value="94.8" lower_limit="92.8" upper_limit="96.3"/>
                    <measurement group_id="O3" value="97.4" lower_limit="94.9" upper_limit="98.9"/>
                    <measurement group_id="O4" value="95.8" lower_limit="93.2" upper_limit="97.6"/>
                    <measurement group_id="O5" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O6" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2: Day 1(N=606,705,306,358,NA,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.6" lower_limit="74.0" upper_limit="80.8"/>
                    <measurement group_id="O2" value="89.2" lower_limit="86.7" upper_limit="91.4"/>
                    <measurement group_id="O3" value="80.4" lower_limit="75.5" upper_limit="84.7"/>
                    <measurement group_id="O4" value="88.0" lower_limit="84.2" upper_limit="91.2"/>
                    <measurement group_id="O5" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O6" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2: Day 22(N=606,705,306,358,NA,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="97.4" upper_limit="99.4"/>
                    <measurement group_id="O2" value="98.3" lower_limit="97.0" upper_limit="99.1"/>
                    <measurement group_id="O3" value="99.0" lower_limit="97.2" upper_limit="99.8"/>
                    <measurement group_id="O4" value="98.3" lower_limit="96.4" upper_limit="99.4"/>
                    <measurement group_id="O5" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O6" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B1: Day 1(N=606,705,306,358,NA,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.5" lower_limit="61.6" upper_limit="69.3"/>
                    <measurement group_id="O2" value="70.9" lower_limit="67.4" upper_limit="74.3"/>
                    <measurement group_id="O3" value="62.4" lower_limit="56.7" upper_limit="67.9"/>
                    <measurement group_id="O4" value="67.9" lower_limit="62.8" upper_limit="72.7"/>
                    <measurement group_id="O5" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O6" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B1: Day 22(N=606,705,306,358,NA,NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4" lower_limit="94.6" upper_limit="97.7"/>
                    <measurement group_id="O2" value="91.8" lower_limit="89.5" upper_limit="93.7"/>
                    <measurement group_id="O3" value="96.4" lower_limit="93.7" upper_limit="98.2"/>
                    <measurement group_id="O4" value="87.7" lower_limit="83.9" upper_limit="90.9"/>
                    <measurement group_id="O5" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O6" value="NA">antigen not immunized</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B2: Day 1(N=606,705,NA,NA,297,361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" lower_limit="70.1" upper_limit="77.2"/>
                    <measurement group_id="O2" value="81.7" lower_limit="78.6" upper_limit="84.5"/>
                    <measurement group_id="O3" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O4" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O5" value="72.7" lower_limit="67.3" upper_limit="77.7"/>
                    <measurement group_id="O6" value="80.9" lower_limit="76.4" upper_limit="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B2: Day 22(N=606,705,NA,NA,297,361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="98.3" upper_limit="99.8"/>
                    <measurement group_id="O2" value="96.2" lower_limit="94.5" upper_limit="97.5"/>
                    <measurement group_id="O3" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O4" value="NA">antigen not immunized</measurement>
                    <measurement group_id="O5" value="99.0" lower_limit="97.1" upper_limit="99.8"/>
                    <measurement group_id="O6" value="95.3" lower_limit="92.6" upper_limit="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>8.Geometric Mean Titres (GMT) in Subjects After Receiving One Dose of Either QIVc, TIV1c Against B2 Strain</title>
        <description>Immunogenicity of QIVc to TIV1c was assessed by GMT in subjects measured by HI assay, three weeks after vaccination with one dose of either QIVc or TIV1c.
Superiority was established if the upper bound of the two-sided 95% CI for the ratio of GMTs (GMT TIV1c /GMT QIVc) for HI antibody does not exceed the superiority margin of 1.</description>
        <time_frame>Three weeks post vaccination (Day 22)</time_frame>
        <population>Analysis was done on FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>QIVc (≥18 Years)</title>
            <description>Subjects received one dose of cell derived quadrivalent influenza vaccine (QIVc)</description>
          </group>
          <group group_id="O2">
            <title>TIV1c (≥18 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV1c (H1N1, H3N2, B1) recommended for 2013-2014 season</description>
          </group>
        </group_list>
        <measure>
          <title>8.Geometric Mean Titres (GMT) in Subjects After Receiving One Dose of Either QIVc, TIV1c Against B2 Strain</title>
          <description>Immunogenicity of QIVc to TIV1c was assessed by GMT in subjects measured by HI assay, three weeks after vaccination with one dose of either QIVc or TIV1c.
Superiority was established if the upper bound of the two-sided 95% CI for the ratio of GMTs (GMT TIV1c /GMT QIVc) for HI antibody does not exceed the superiority margin of 1.</description>
          <population>Analysis was done on FAS population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1311"/>
                <count group_id="O2" value="664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1(N=1311,664)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.9" lower_limit="43.3" upper_limit="48.8"/>
                    <measurement group_id="O2" value="55.7" lower_limit="51.6" upper_limit="60.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22(N=1311,664)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.4" lower_limit="127.6" upper_limit="143.7"/>
                    <measurement group_id="O2" value="91.7" lower_limit="85.7" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority of immune responses of QIVc to TIV1c in terms of ratios of GMT against influenza strain B2</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The upper bound of the 2-sided 95% CI for the ratio of GMTs (GMT TIV1c or TIV2c /GMT QIVc) for HI antibody should not exceed the superiority margin of 1.</non_inferiority_desc>
            <param_type>Ratios of GMT</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>9.Percentages of Subjects Achieving Seroconversion After One Dose of Either QIVc, TIV1c Against B2 Strain</title>
        <description>Immunogenicity of QIVc to TIV1c was assessed in terms of percentages of subjects showing seroconversion or significant increase in HI antibody titers, against influenza strain B2, three weeks (day 22) after vaccination with QIVc or TIV1c Superiority was established if the upper bound of the two-sided 95% CI for the difference between seroconversion rates (% seroconversion TIV1c – % seroconversion QIVc) for HI antibody in ≥ 18 years age group does not exceed the margin of 0 points</description>
        <time_frame>Three weeks post vaccination (Day 22)</time_frame>
        <population>Analysis was done on FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>QIVc (≥18 Years)</title>
            <description>Subjects received one dose of cell derived quadrivalent influenza vaccine (QIVc)</description>
          </group>
          <group group_id="O2">
            <title>TIV1c (≥18 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV1c (H1N1, H3N2, B1) recommended for 2013-2014 season</description>
          </group>
        </group_list>
        <measure>
          <title>9.Percentages of Subjects Achieving Seroconversion After One Dose of Either QIVc, TIV1c Against B2 Strain</title>
          <description>Immunogenicity of QIVc to TIV1c was assessed in terms of percentages of subjects showing seroconversion or significant increase in HI antibody titers, against influenza strain B2, three weeks (day 22) after vaccination with QIVc or TIV1c Superiority was established if the upper bound of the two-sided 95% CI for the difference between seroconversion rates (% seroconversion TIV1c – % seroconversion QIVc) for HI antibody in ≥ 18 years age group does not exceed the margin of 0 points</description>
          <population>Analysis was done on FAS population</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1311"/>
                <count group_id="O2" value="664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6" lower_limit="34.0" upper_limit="39.3"/>
                    <measurement group_id="O2" value="17.2" lower_limit="14.4" upper_limit="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority of immune responses of QIVc to TIV1c in terms of seroconversion rates against influenza strain B2</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The upper bound of the 2-sided 95% CI for the difference between seroconversion rates (% seroconversion TIV1c or TIV2c – % seroconversion QIVc) for HI antibody should not exceed the margin of 0 points.</non_inferiority_desc>
            <param_type>Difference between seroconversion rates</param_type>
            <param_value>-19.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.2</ci_lower_limit>
            <ci_upper_limit>-15.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>10.GMT in Subjects After Receiving One Dose of Either QIVc, TIV2c Against B1 Strain</title>
        <description>Immunogenicity of QIVc to TIV2c was assessed by GMT in subjects measured by HI assay, three weeks after vaccination with one dose of either QIVc or TIV2c.
Superiority was established if the upper bound of the two-sided 95% CI for the ratio of GMTs (GMT TIV2c /GMT QIVc) for HI antibody does not exceed the superiority margin of 1</description>
        <time_frame>Three weeks post vaccination (Day 22)</time_frame>
        <population>Analysis was done on FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>QIVc (≥18 Years)</title>
            <description>Subjects received one dose of cell derived quadrivalent influenza vaccine (QIVc)</description>
          </group>
          <group group_id="O2">
            <title>TIV2c (≥18 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV2c that contains an alternate B strain compared to what is recommended for 2013-2014</description>
          </group>
        </group_list>
        <measure>
          <title>10.GMT in Subjects After Receiving One Dose of Either QIVc, TIV2c Against B1 Strain</title>
          <description>Immunogenicity of QIVc to TIV2c was assessed by GMT in subjects measured by HI assay, three weeks after vaccination with one dose of either QIVc or TIV2c.
Superiority was established if the upper bound of the two-sided 95% CI for the ratio of GMTs (GMT TIV2c /GMT QIVc) for HI antibody does not exceed the superiority margin of 1</description>
          <population>Analysis was done on FAS population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1311"/>
                <count group_id="O2" value="658"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1(N=1311,658)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.7" lower_limit="56.4" upper_limit="63.0"/>
                    <measurement group_id="O2" value="43.8" lower_limit="40.3" upper_limit="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22(N=1311,657)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.1" lower_limit="167.8" upper_limit="187.1"/>
                    <measurement group_id="O2" value="76.3" lower_limit="70.4" upper_limit="82.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority of immune responses of QIVc to TIV2c in terms of ratios of GMT against influenza strain B1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The upper bound of the 2-sided 95% CI for the ratio of GMTs (GMT TIV1c or TIV2c /GMT QIVc) for HI antibody should not exceed the superiority margin of 1.</non_inferiority_desc>
            <param_type>Ratios of GMT</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>11.Percentages of Subjects Achieving Seroconversion After One Dose of Either QIVc, TIV2c Against B1 Strain</title>
        <description>Immunogenicity of QIVc to TIV2c in terms of percentages of subjects showing seroconversion or significant increase in HI antibody titers, against influenza strain B1, three weeks (day 22) after vaccination with QIVc or TIV2c Superiority was established if the upper bound of the two-sided 95% CI for the difference between seroconversion rates (% seroconversion TIV2c – % seroconversion QIVc) for HI antibody in ≥ 18 years age group does not exceed the margin of 0 points</description>
        <time_frame>Three weeks post vaccination (Day 22)</time_frame>
        <population>Analysis was done on FAS population</population>
        <group_list>
          <group group_id="O1">
            <title>QIVc (≥18 Years)</title>
            <description>Subjects received one dose of cell derived quadrivalent influenza vaccine (QIVc)</description>
          </group>
          <group group_id="O2">
            <title>TIV2c (≥18 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV2c that contains an alternate B strain compared to what is recommended for 2013-2014</description>
          </group>
        </group_list>
        <measure>
          <title>11.Percentages of Subjects Achieving Seroconversion After One Dose of Either QIVc, TIV2c Against B1 Strain</title>
          <description>Immunogenicity of QIVc to TIV2c in terms of percentages of subjects showing seroconversion or significant increase in HI antibody titers, against influenza strain B1, three weeks (day 22) after vaccination with QIVc or TIV2c Superiority was established if the upper bound of the two-sided 95% CI for the difference between seroconversion rates (% seroconversion TIV2c – % seroconversion QIVc) for HI antibody in ≥ 18 years age group does not exceed the margin of 0 points</description>
          <population>Analysis was done on FAS population</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1311"/>
                <count group_id="O2" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7" lower_limit="37.0" upper_limit="42.4"/>
                    <measurement group_id="O2" value="18.0" lower_limit="15.1" upper_limit="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority of immune responses of QIVc to TIV2c in terms of seroconversion rates against influenza strain B1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The upper bound of the 2-sided 95% CI for the difference between seroconversion rates (% seroconversion TIV1c or TIV2c – %seroconversion QIVc) for HI antibody should not exceed the margin of 0 points.</non_inferiority_desc>
            <param_type>Difference between seroconversion rates</param_type>
            <param_value>-21.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.5</ci_lower_limit>
            <ci_upper_limit>-17.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12.Number of Subjects Reporting Solicited Adverse Events (AEs) After One Dose of Either QIVc, TIV1c or TIV2c by Overall Age Group</title>
        <description>Safety was assessed in terms of number (%) of subjects reporting solicited local and systemic reactions, day 1 to 7 after vaccination with one dose of either four (4) strain inactivated quadrivalent cell based influenza vaccine (QIVc) or trivalent inactivated influenza vaccine (TIV1c or TIV2c)</description>
        <time_frame>Day 1 to 7 post vaccination</time_frame>
        <population>Analysis was done on solicited safety data set i.e. all subjects in the exposed set with solicited adverse event data</population>
        <group_list>
          <group group_id="O1">
            <title>QIVc (≥18 Years)</title>
            <description>Subjects received one dose of cell derived quadrivalent influenza vaccine (QIVc)</description>
          </group>
          <group group_id="O2">
            <title>TIV1c (≥18 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV1c (H1N1, H3N2, B1) recommended for 2013-2014 season</description>
          </group>
          <group group_id="O3">
            <title>TIV2c (≥18 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV2c that contains an alternate B strain compared to what is recommended for 2013-2014</description>
          </group>
        </group_list>
        <measure>
          <title>12.Number of Subjects Reporting Solicited Adverse Events (AEs) After One Dose of Either QIVc, TIV1c or TIV2c by Overall Age Group</title>
          <description>Safety was assessed in terms of number (%) of subjects reporting solicited local and systemic reactions, day 1 to 7 after vaccination with one dose of either four (4) strain inactivated quadrivalent cell based influenza vaccine (QIVc) or trivalent inactivated influenza vaccine (TIV1c or TIV2c)</description>
          <population>Analysis was done on solicited safety data set i.e. all subjects in the exposed set with solicited adverse event data</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1319"/>
                <count group_id="O2" value="670"/>
                <count group_id="O3" value="663"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="551"/>
                    <measurement group_id="O2" value="240"/>
                    <measurement group_id="O3" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration(hardness)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema (redness)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site ecchymosis(bruising)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="443"/>
                    <measurement group_id="O2" value="186"/>
                    <measurement group_id="O3" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="376"/>
                    <measurement group_id="O2" value="192"/>
                    <measurement group_id="O3" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="109"/>
                    <measurement group_id="O3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of analgesics / antipyretics for prophylasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of analgesics / antipyretics for treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>13.Number of Subjects Reporting Unsolicited Adverse Events (AEs) After One Dose of Either QIVc, TIV1c or TIV2c by Overall Age Group</title>
        <description>Safety was assessed in terms of number (%) of subjects reporting unsolicited AEs (day 1 to 22 after vaccination), serious adverse events (SAEs), medically attended AEs, AEs leading to withdrawal from the study, new onset of chronic diseases (NOCDs), and concomitant medications (day 1 to day 181 post vaccination) after receiving one dose of either four (4) strain inactivated quadrivalent cell based influenza vaccine (QIVc) or trivalent inactivated influenza vaccine (TIV1c or TIV2c)</description>
        <time_frame>Day 1 to 181 post vaccination</time_frame>
        <population>Analysis was done on unsolicited safety data set i.e. all subjects in the exposed set with unsolicited adverse event data</population>
        <group_list>
          <group group_id="O1">
            <title>QIVc (≥18 Years)</title>
            <description>Subjects received one dose of cell derived quadrivalent influenza vaccine (QIVc)</description>
          </group>
          <group group_id="O2">
            <title>TIV1c (≥18 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV1c (H1N1, H3N2, B1) recommended for 2013-2014 season</description>
          </group>
          <group group_id="O3">
            <title>TIV2c (≥18 Years)</title>
            <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV2c that contains an alternate B strain compared to what is recommended for 2013-2014</description>
          </group>
        </group_list>
        <measure>
          <title>13.Number of Subjects Reporting Unsolicited Adverse Events (AEs) After One Dose of Either QIVc, TIV1c or TIV2c by Overall Age Group</title>
          <description>Safety was assessed in terms of number (%) of subjects reporting unsolicited AEs (day 1 to 22 after vaccination), serious adverse events (SAEs), medically attended AEs, AEs leading to withdrawal from the study, new onset of chronic diseases (NOCDs), and concomitant medications (day 1 to day 181 post vaccination) after receiving one dose of either four (4) strain inactivated quadrivalent cell based influenza vaccine (QIVc) or trivalent inactivated influenza vaccine (TIV1c or TIV2c)</description>
          <population>Analysis was done on unsolicited safety data set i.e. all subjects in the exposed set with unsolicited adverse event data</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1324"/>
                <count group_id="O2" value="673"/>
                <count group_id="O3" value="665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any possibly related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possibly/probably related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to study withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically attended AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="344"/>
                    <measurement group_id="O2" value="172"/>
                    <measurement group_id="O3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NOCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death(N=1355,676,669)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited AEs were collected from day 1to day 7 post vaccination, unsolicited AEs were collected from day 1 to day 22 post vaccination and SAEs were collected from day 1 to day 181</time_frame>
      <desc>All the unsolicited AEs were reported by non-systematic assessment and the solicited AEs were reported by systemic assessment.
For SAEs- analysis was done on Unsolicited safety set. For Other Aes-analysis was done on overall safety set.</desc>
      <group_list>
        <group group_id="E1">
          <title>QIVc (≥18 Years)</title>
          <description>Subjects received one dose of cell derived quadrivalent influenza vaccine (QIVc)</description>
        </group>
        <group group_id="E2">
          <title>TIV1c (≥ 18 Years)</title>
          <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV1c (H1N1, H3N2, B1) recommended for 2013-2014 season</description>
        </group>
        <group group_id="E3">
          <title>TIV2c (≥18 Years)</title>
          <description>Subjects received one dose of cell derived trivalent influenza vaccine TIV2c that contains an alternate B strain compared to what is recommended for 2013-2014</description>
        </group>
        <group group_id="E4">
          <title>Total</title>
          <description>Total Number of Subjects</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="95" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>HISTIOCYTOSIS HAEMATOPHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS CORONARY ARTERY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>LOWER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>STRANGULATED HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>MENINGITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>PNEUMONIA LEGIONELLA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE ILEUS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>MUSCLE HAEMORRHAGE</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYELOID LEUKAEMIA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>CERVIX CARCINOMA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL ADENOCARCINOMA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL CANCER</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>METASTASES TO LUNG</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>OVARIAN ADENOMA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>TRANSITIONAL CELL CARCINOMA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>AMYOTROPHIC LATERAL SCLEROSIS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>GENERALISED TONIC-CLONIC SEIZURE</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ALCOHOLISM</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>BIPOLAR DISORDER</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>ENDOMETRIOSIS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>IMPLANTABLE DEFIBRILLATOR INSERTION</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="681" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="332" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="335" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="1348" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="188" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="181" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="144" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="183" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="377" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="315" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>INJECTION SITE HAEMORRHAGE</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="117" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>INJECTION SITE INDURATION</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="249" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="444" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="187" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="195" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="826" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="167" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="212" subjects_at_risk="2662"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="322" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="191" subjects_at_risk="1324"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="673"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="665"/>
                <counts group_id="E4" subjects_affected="377" subjects_at_risk="2662"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

